NCT06977282

Brief Summary

The aim of this observational study is to investigate the relationship between pain severity and alterations in bone-derived and brain-derived signaling molecules (including serum neurotransmitters and inflammatory cytokines), as well as structural and functional changes in the ventrolateral periaqueductal gray (vlPAG) region in patients with kidney-deficiency type knee osteoarthritis (KOA). The central question it seeks to address is whether changes in these signaling molecules and vlPAG alterations are associated with the degree of pain. Patients scheduled to undergo total knee arthroplasty (TKA) due to KOA will be enrolled prior to surgery. Before the operation, they will undergo questionnaire assessments, physical examinations, imaging evaluations, and blood sample collection. The resected tibial plateau tissue obtained during surgery will be used for subsequent laboratory analyses.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Jun 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Jun 2025Dec 2026

First Submitted

Initial submission to the registry

April 12, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 18, 2025

Completed
28 days until next milestone

Study Start

First participant enrolled

June 15, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Last Updated

May 18, 2025

Status Verified

April 1, 2025

Enrollment Period

1.5 years

First QC Date

April 12, 2025

Last Update Submit

May 16, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index

    The WOMAC Index is a validated instrument used to assess pain, stiffness, and physical dysfunction in patients with osteoarthritis. It comprises 3 subscales with a total of 24 items, yielding a total score ranging from 0 to 96, where higher scores indicate more severe symptoms and greater functional impairment.

    Participants were tested immediately after being included in the study.

Secondary Outcomes (16)

  • Visual Analog Scale (VAS) score

    Participants were tested immediately after being included in the study.

  • Pattern Element Analysis

    Participants were tested immediately after being included in the study.

  • Function of Knee Joint

    Participants were tested immediately after being included in the study.

  • Volume of Subchondral Cystic Lesions

    Participants were tested immediately after being included in the study.

  • Brain Region Structure

    Participants were tested immediately after being included in the study.

  • +11 more secondary outcomes

Study Arms (2)

KOA

Patients with knee osteoarthritis of renal deficiency type who meet the diagnostic criteria

HC

Healthy volunteers

Eligibility Criteria

Age60 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with knee osteoarthritis of kidney deficiency type from the Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine. And the healthy volunteers recruited by the research team.

You may qualify if:

  • Clinical diagnosis of KOA
  • Age between 60-70 years.
  • Kellgren-Lawrence grade IV on anteroposterior and lateral knee X-rays.
  • Scheduled for total knee arthroplasty.
  • Voluntarily signs informed consent.

You may not qualify if:

  • Clinical diagnosis of ankylosing spondylitis, rheumatoid arthritis, gout, or other related conditions.
  • Presence of metabolic bone diseases, acute trauma, malignancies, infections, or other complications severely affecting knee function.
  • Use of drugs affecting bone metabolism (e.g., corticosteroids, zoledronic acid) within the past 6 months.
  • Presence of psychiatric disorders or serious cardiovascular, pulmonary, renal, hepatic, hematologic, or other systemic diseases.
  • Contraindications to MRI.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Tibial plateau samples obtained from KOA patients during total knee arthroplasty.

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Resident Physician

Study Record Dates

First Submitted

April 12, 2025

First Posted

May 18, 2025

Study Start

June 15, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 30, 2026

Last Updated

May 18, 2025

Record last verified: 2025-04